Skip to content

Nuvation Bio NUVB License — Milestone Received

Similar metrics at other companies

Crinetics Pharmaceuticals logo
CRNXLicense — Milestone revenue
$1.5M
Cytokinetics logo
CYTKLicense And Milestone Revenues — Revenue
$11.93M
Axsome Therapeutics logo
AXSMMilestone Revenue — Revenue
$500K
Incyte logo
INCYMilestone and contract revenues — Total revenues
$17M
Dianthus Therapeutics logo
DNTHMilestone — Revenue Recognition Milestone Method Pending
$15M0.0%
Exelixis logo
EXELLicense revenues — Revenue from contract with customer, commercial sales milestone
$5.3M+393%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept nuvb:MilestoneReceived.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's license — milestone received.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's license — milestone received?
Nuvation Bio (NUVB) reported license — milestone received of $21.2M in Q4 2025.
What does license — milestone received mean?
This metric captures the cash or revenue recognized from milestone payments received from partners upon the successful completion of specific development or regulatory events. It serves as a validation of the clinical progress of the company's therapeutic candidates and provides non-dilutive capital to support ongoing operations. High levels of milestone receipts indicate successful execution of the company's R&D strategy and strong partner engagement.